Clinical Trials

Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma or Leukemia

A Phase III Randomized, Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

Temp clos 4/18/08
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Myelodysplastic Syndrome (MDS)

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults
with Untreated Acute Lymphoblastic Leukemia

A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Patients Randomized to Early Intervention versus Observation with Later Treatment in the High Risk Genetic Subset with IGVH Unmutated Disease

Dose Escalation and Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years

Phase II Study of Maintenance Therapy with Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients
< 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)

A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain
Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)

AML Companion-Novel markers

A Phase II Randomized Study of OSI-774 (Erlotinib) with or without Carboplatin/ Paclitaxel in Patients with Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers

Temp clos 5/17/08
Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study

A Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma

A Phase II Study of Dasatinib in Patients with Chemo-sensitive
Relapsed Small Cell Lung Cancer

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced,
Stage IIIB/IV Non-Small Cell Lung Cancer

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

Development of a Geriatric Assessment Measure for Older Patients with Cancer

Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study

Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone
Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer